Stacy Silvers, MD
Allergy & Immunology · Austin, TXNPI 1467629337
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,120 of the $26,206 with a category attached, or 61.5%. Genentech USA, Inc. accounts for 64.9% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $11,835, more than ten times the $271 reported in 2019.
Across 194 payments — averaging $135.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$17K
- ARS Pharmaceuticals Operations, Inc.$2K
- Optinose US, Inc.$2K
- Alk-abello, Inc$1K
- AstraZeneca$973
- Amgen$611
- plus $2K from 20 others
Across 1 payment — averaging $4188.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$4K
What the payments were for
- Consulting fees$2,1258%
- Speaking & faculty fees$16,12062%
- Travel & lodging$1,5216%
- Food & beverage$4,94119%
- Education$1,5006%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 22 | $17,017 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $2,267 |
| Optinose US, Inc. | 7 | $1,624 |
| Alk-abello, Inc | 6 | $1,298 |
| AstraZeneca | 30 | $973 |
| Amgen | 14 | $611 |
| GSK | 35 | $572 |
| Novartis | 14 | $502 |
| Regeneron Healthcare Solutions, Inc. | 19 | $442 |
| Sanofi | 8 | $210 |
| Kaleo, Inc. | 10 | $190 |
| Inspire Medical Systems, Inc. | 2 | $94 |
| Phadia US Inc. | 3 | $73 |
| Aerin Medical Inc. | 1 | $39 |
| Acclarent, Inc | 2 | $39 |
| AbbVie | 2 | $30 |
| Pfizer | 1 | $30 |
| Neurent Medical Limited | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Pharming Healthcare, Inc. | 1 | $26 |
| Grifols USA, LLC | 1 | $23 |
| Biocryst US Sales Co., LLC | 1 | $23 |
| Covis Pharma GmbH | 1 | $21 |
| LEO Pharma Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,206 in reported general payments places this provider in the 85th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Montelukast Sodium | 12 | $98 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Austin
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Michael VolzAustin$78K
- Allen LiebermanAustin$39K
- Ojas PatelAustin$23K
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Lara GrossDallas$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.